PMID- 31284866
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20200423
IS  - 1875-6360 (Electronic)
IS  - 1573-3971 (Linking)
VI  - 15
IP  - 4
DP  - 2019
TI  - Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and 
      Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it.
PG  - 329-335
LID - 10.2174/1573397115666190708113601 [doi]
AB  - BACKGROUND: Many patients may have resistance to TNF-blockers. These drugs may 
      induce neutralizing antibodies. The determination of the drug levels of 
      TNF-blockers and Anti-Drug Antibodies (ADAs) against TNF-blockers may help to 
      make clinical decisions. OBJECTIVES: The objective of this study was to associate 
      and predict the drug levels of TNFblockers and ADAs in relation to disease 
      activity in patients with Spondyloarthritis (SpA) and Rheumatoid Arthritis (RA). 
      METHODS: Cross-sectional study including patients fulfilling ASAS classification 
      criteria for SpA and 2010 ACR-EULAR classification criteria for RA. These 
      patients were treated with Adalimumab (ADA), Infliximab (IFX), and Etanercept 
      (ETN). A bivariate analysis and the chi-square test were performed to evaluate 
      the association of ADAs and drug levels with activity measures for SpA and RA. 
      Five regression models analyzing drug levels, ADAs and disease activity measures 
      using a multiple linear regression were performed in order to evaluate the 
      prediction of ADAs and drug levels in relation to disease activity. RESULTS: In 
      SpA, IFX levels were associated with BASDAI (Bath Ankylosing Spondylitis Disease 
      Activity Index) (p=0.034). In RA, total drug levels were associated with 
      DAS28-ESR (28 joint Disease activity Score-erythrocyte sedimentation rate), 
      (p=0.008), DAS28-CRP (p=0.042), CDAI (Clinical Disease Activity Index) (p=0.047) 
      and SDAI (Simple Disease activity index), (p=0.017). ADA levels had association 
      with CDAI (p=0.002) and SDAI (p=0.002). IFX levels were associated with a 
      DAS28-ESR (p=0.044), DAS28-CRP (p=0.022) and SDAI (p=0.022). ADAs were associated 
      in SpA with BASDAI (p=0.027). Drug levels and ADAs did not predict disease 
      activity in patients with SpA or RA. CONCLUSION: ADAs and drug levels of anti-TNF 
      are associated with disease activity measures in patients with SpA and RA. 
      However, they cannot predict clinical activity in these conditions.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Padilla-Martinez, Erika Marcela
AU  - Padilla-Martinez EM
AD  - Department of Rheumatology and Immunology, Hospital Militar Central, Bogota, 
      Colombia.
FAU - Romero-Sanchez, Consuelo
AU  - Romero-Sanchez C
AD  - Department of Rheumatology and Immunology, Grupo de Inmunologia Clinica Aplicada, 
      School of Medicine, Hospital Militar Central/ Universidad Militar Nueva Granada, 
      Bogota, Colombia.
FAU - Bello-Gualtero, Juan Manuel
AU  - Bello-Gualtero JM
AD  - Department of Rheumatology and Immunology, Grupo de Inmunologia Clinica Aplicada, 
      School of Medicine, Hospital Militar Central/ Universidad Militar Nueva Granada, 
      Bogota, Colombia.
FAU - Mesa-Betancourt, Ana Maria
AU  - Mesa-Betancourt AM
AD  - Department of Rheumatology and Immunology, Hospital Militar Central, Bogota, 
      Colombia.
FAU - Bautista-Molano, Wilson
AU  - Bautista-Molano W
AD  - Department of Rheumatology and Immunology, Grupo de Inmunologia Clinica Aplicada, 
      School of Medicine, Hospital Militar Central/ Universidad Militar Nueva Granada, 
      Bogota, Colombia.
FAU - Valle-O, Rafael
AU  - Valle-O R
AD  - Department of Rheumatology and Immunology, Hospital Militar Central, Bogota, 
      Colombia.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Rheumatol Rev
JT  - Current rheumatology reviews
JID - 101261938
RN  - 0 (Antibodies)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies/blood
MH  - Arthritis, Rheumatoid/drug therapy/*immunology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Severity of Illness Index
MH  - Spondylarthritis/drug therapy/*immunology
MH  - Tumor Necrosis Factor Inhibitors/blood/*immunology/therapeutic use
OTO - NOTNLM
OT  - Antibodies
OT  - inflammatory bowel disease
OT  - peripheral arthritis
OT  - rheumatoid arthritis
OT  - spondyloarthritis
OT  - tumoral necrosis factor.
EDAT- 2019/07/10 06:00
MHDA- 2020/04/24 06:00
CRDT- 2019/07/10 06:00
PHST- 2018/09/30 00:00 [received]
PHST- 2018/12/13 00:00 [revised]
PHST- 2018/12/17 00:00 [accepted]
PHST- 2019/07/10 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
PHST- 2019/07/10 06:00 [entrez]
AID - CRR-EPUB-99455 [pii]
AID - 10.2174/1573397115666190708113601 [doi]
PST - ppublish
SO  - Curr Rheumatol Rev. 2019;15(4):329-335. doi: 10.2174/1573397115666190708113601.